$1.32 Billion in Sales Expected for AMETEK, Inc. (NYSE:AME) This Quarter

Wall Street analysts predict that AMETEK, Inc. (NYSE:AME) will announce $1.32 billion in sales for the current fiscal quarter, Zacks reports. Five analysts have made estimates for AMETEK’s earnings, with the lowest sales estimate coming in at $1.32 billion and the highest estimate coming in at $1.33 billion. AMETEK reported sales of $1.21 billion during the same quarter last year, which would suggest a positive year over year growth rate of 9.1%. The company is expected to announce its next earnings results before the market opens on Tuesday, July 30th.

According to Zacks, analysts expect that AMETEK will report full-year sales of $5.25 billion for the current financial year, with estimates ranging from $5.24 billion to $5.27 billion. For the next financial year, analysts anticipate that the firm will post sales of $5.46 billion, with estimates ranging from $5.42 billion to $5.53 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow AMETEK.

AMETEK (NYSE:AME) last announced its quarterly earnings results on Wednesday, May 1st. The technology company reported $1.00 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.97 by $0.03. AMETEK had a net margin of 16.14% and a return on equity of 18.56%. The business had revenue of $1.29 billion for the quarter, compared to analysts’ expectations of $1.28 billion. During the same quarter last year, the firm earned $0.79 EPS. The firm’s revenue for the quarter was up 9.8% compared to the same quarter last year.

Several equities analysts recently weighed in on the stock. Morgan Stanley set a $226.00 price target on shares of S&P Global and gave the company a “hold” rating in a research report on Friday, May 3rd. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 150 ($1.96) price target on shares of Tharisa in a research report on Wednesday, May 15th. ValuEngine cut shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. KeyCorp reaffirmed a “hold” rating on shares of Ball in a research report on Thursday, May 2nd. Finally, Zacks Investment Research cut shares of Essential Properties Realty Trust from a “buy” rating to a “hold” rating in a research report on Thursday, June 13th. Fifteen research analysts have rated the stock with a buy rating, AMETEK presently has an average rating of “Buy” and a consensus price target of $91.50.

In other AMETEK news, Director Dennis K. Williams sold 1,570 shares of AMETEK stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $87.00, for a total transaction of $136,590.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Thomas M. Montgomery sold 5,602 shares of AMETEK stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $88.50, for a total transaction of $495,777.00. Following the transaction, the vice president now directly owns 26,419 shares in the company, valued at approximately $2,338,081.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 93,370 shares of company stock worth $8,072,702. Insiders own 0.80% of the company’s stock.

Several institutional investors have recently bought and sold shares of AME. Clark Capital Management Group Inc. purchased a new stake in shares of AMETEK during the 2nd quarter worth approximately $474,000. Nisa Investment Advisors LLC increased its stake in shares of AMETEK by 1.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 75,575 shares of the technology company’s stock worth $6,865,000 after purchasing an additional 865 shares during the last quarter. CENTRAL TRUST Co increased its stake in shares of AMETEK by 4.6% during the 2nd quarter. CENTRAL TRUST Co now owns 3,103 shares of the technology company’s stock worth $278,000 after purchasing an additional 137 shares during the last quarter. Smith Salley & Associates increased its stake in shares of AMETEK by 4.9% during the 2nd quarter. Smith Salley & Associates now owns 100,194 shares of the technology company’s stock worth $9,102,000 after purchasing an additional 4,645 shares during the last quarter. Finally, Diversified Trust Co increased its stake in shares of AMETEK by 4.3% during the 2nd quarter. Diversified Trust Co now owns 4,200 shares of the technology company’s stock worth $382,000 after purchasing an additional 175 shares during the last quarter. 85.73% of the stock is currently owned by hedge funds and other institutional investors.

NYSE AME traded up $1.41 during trading hours on Friday, hitting $91.00. The company’s stock had a trading volume of 1,154,292 shares, compared to its average volume of 1,198,326. AMETEK has a 52 week low of $63.14 and a 52 week high of $92.30. The stock has a market capitalization of $20.73 billion, a P/E ratio of 27.66, a PEG ratio of 2.29 and a beta of 1.24. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.91 and a quick ratio of 1.27. The company’s 50-day moving average price is $86.96.

The company also recently announced a quarterly dividend, which was paid on Friday, June 28th. Shareholders of record on Friday, June 14th were given a dividend of $0.14 per share. The ex-dividend date of this dividend was Thursday, June 13th. This represents a $0.56 annualized dividend and a dividend yield of 0.62%. AMETEK’s dividend payout ratio is currently 17.02%.

AMETEK Company Profile

AMETEK, Inc manufactures and sells electronic instruments and electromechanical devices worldwide. The company's Electronic Instruments segment offers advanced instruments for the process, aerospace, power, and industrial markets; process control instruments for the oil and gas, petrochemical, pharmaceutical, semiconductor, automation, and food and beverage industries; and instruments to the laboratory equipment, ultra-precision manufacturing, medical, and test and measurement markets.

Further Reading: What is the Beige Book?

Get a free copy of the Zacks research report on AMETEK (AME)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AMETEK (NYSE:AME)

Receive News & Ratings for AMETEK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMETEK and related companies with MarketBeat.com's FREE daily email newsletter.